Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

pr_newswire_finance · 2026-08-24 · Bullish AI sentiment

$ABT

TAIPEI, Aug. 23, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate...

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.